Welgen

Welgen is a long-established, privately-held service provider in the biomedical research tools sector, specializing in high-titer viral vector production and related molecular biology services. The company operates a fee-for-service business model, generating revenue by executing custom projects for research clients, from vector construction to large-scale amplification and purification. Its strategic location in a major biotech hub and its two-decade track record position it as a reliable partner for researchers needing complex gene delivery tools. Welgen's focus is exclusively on enabling research, not on developing its own therapeutic pipeline.

Suite of optimized molecular biology and virology techniques for viral vector (adenovirus, lentivirus, AAV, retrovirus) production, purification, and engineering, alongside gene silencing (shRNA), CRISPR, and stable cell line generation services.

Welgen competes in the fragmented life science CRO and research tools market. Key competitors range from large players like Thermo Fisher Scientific and Charles River Laboratories (through their custom services) to numerous specialized viral vector CROs (e.g., Vigene Biosciences, VectorBuilder). Differentiation is based on technical expertise, turnaround time, quality, price, and customer service.